Integer Holdings Co. (NYSE:ITGR) Receives $147.67 Average Target Price from Analysts

Shares of Integer Holdings Co. (NYSE:ITGR) have received a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $149.00.

Several analysts recently issued reports on ITGR shares. Oppenheimer lowered Integer from an “outperform” rating to a “market perform” rating in a report on Friday, February 21st. Truist Financial lifted their price target on Integer from $147.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Benchmark increased their price objective on Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, February 21st. KeyCorp boosted their target price on shares of Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, Wells Fargo & Company restated an “overweight” rating and set a $160.00 price target on shares of Integer in a report on Tuesday, December 3rd.

Integer Trading Down 0.5 %

NYSE:ITGR opened at $117.76 on Wednesday. The stock has a market cap of $3.96 billion, a PE ratio of 35.05, a price-to-earnings-growth ratio of 1.72 and a beta of 1.24. Integer has a fifty-two week low of $107.11 and a fifty-two week high of $146.36. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09. The stock’s 50-day moving average is $134.11 and its two-hundred day moving average is $132.68.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). Integer had a net margin of 6.92% and a return on equity of 11.65%. The company had revenue of $449.50 million for the quarter, compared to analysts’ expectations of $446.28 million. As a group, equities research analysts forecast that Integer will post 6.01 earnings per share for the current fiscal year.

Institutional Trading of Integer

Several large investors have recently modified their holdings of the company. Janney Montgomery Scott LLC lifted its position in Integer by 2.6% during the 3rd quarter. Janney Montgomery Scott LLC now owns 9,668 shares of the medical equipment provider’s stock worth $1,257,000 after acquiring an additional 246 shares during the last quarter. Crossmark Global Holdings Inc. lifted its position in shares of Integer by 14.7% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 2,899 shares of the medical equipment provider’s stock worth $377,000 after purchasing an additional 372 shares during the last quarter. State of New Jersey Common Pension Fund D lifted its position in shares of Integer by 1.8% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 15,582 shares of the medical equipment provider’s stock worth $2,026,000 after purchasing an additional 268 shares during the last quarter. Versor Investments LP boosted its stake in Integer by 48.0% during the 3rd quarter. Versor Investments LP now owns 3,404 shares of the medical equipment provider’s stock valued at $443,000 after purchasing an additional 1,104 shares during the period. Finally, North Growth Management Ltd. grew its holdings in Integer by 7.6% in the 3rd quarter. North Growth Management Ltd. now owns 99,000 shares of the medical equipment provider’s stock valued at $12,857,000 after buying an additional 7,000 shares during the last quarter. 99.29% of the stock is owned by institutional investors.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.